Scott Hecker is senior vice president of chemistry and chemical development with over 30 years of industry experience leading medicinal chemistry and manufacturing in anti-infective drug discovery and development.
Scott began his career in industry at Pfizer Inc. as a medicinal chemist in antibacterial drug discovery and then joined Microcide Pharmaceuticals/Essential Therapeutics, where he led teams in the discovery of novel anti-infective drug candidates. He moved to Metabasis Therapeutics Inc., where he oversaw the discovery and early development of drug candidates for diabetes, hyperlipidemia and hepatitis C in programs that advanced in development under partnerships with Merck and Roche. Scott later joined Mpex Pharmaceuticals/Rempex Pharmaceuticals, where he was a founding member of the beta-lactamase inhibitor program that discovered the now FDA-approved agent, vaborbactam. Following the acquisition of Rempex Pharmaceuticals, Inc. by The Medicines Company, he oversaw active pharmaceutical ingredients manufacturing and early discovery programs. Scott has more than 40 publications and more than 55 U.S. patents.
Scott earned his Bachelor of Arts in chemistry from Wesleyan University in Middletown, Connecticut, and his Doctor of Philosophy in chemistry from the University of California, Berkeley.
